VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32946801/

⇱ Multisystem inflammatory syndrome associated with COVID-19 from the pediatric emergency physician's point of view - PubMed


Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

Objective: Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19) is a rare and challenging diagnosis requiring early treatment. The diagnostic criteria involve clinical, laboratory, and complementary tests. This review aims to draw pediatrician attention to this diagnosis, suggesting early treatment strategies, and proposing a pediatric emergency care flowchart.

Sources: The PubMed/MEDLINE/WHO COVID-19 databases were reviewed for original and review articles, systematic reviews, meta-analyses, case series, and recommendations from medical societies and health organizations published through July 3, 2020. The reference lists of the selected articles were manually searched to identify any additional articles.

Summary of the findings: COVID-19 infection is less severe in children than in adults, but can present as MIS-C, even in patients without comorbidities. There is evidence of an exacerbated inflammatory response with potential systemic injury, and it may present with aspects similar to those of Kawasaki disease, toxic shock syndrome, and macrophage activation syndrome. MIS-C can develop weeks after COVID-19 infection, suggesting an immunomediated cause. The most frequent clinical manifestations include fever, gastrointestinal symptoms, rash, mucous membrane changes, and cardiac dysfunction. Elevated inflammatory markers, lymphopenia, and coagulopathy are common laboratory findings. Supportive treatment and early immunomodulation can control the intense inflammatory response and reduce complications and mortality.

Conclusions: MIS-C associated with COVID-19 is serious, rare, and potentially fatal. The emergency department pediatrician must recognize and treat it early using immunomodulatory strategies to reduce systemic injury. Further studies are needed to identify the disease pathogenesis and establish the most appropriate treatment.

Keywords: Coronavirus disease (COVID-19); Emergency department; Inflammatory syndrome; Kawasaki disease; Pediatrics; SARS-CoV-2.

PubMed Disclaimer

Figures

👁 Figure 1
Figure 1
Interrelationship between the four plasma mediator systems triggered by the activation of factor XII (Hageman factor). Source: Kumar et al.
👁 Figure 2
Figure 2
COVID 19 disease and MIS-C related to COVID-19. The figure illustrates 4 escalating progressive phases of the disease, according to evolution, severity, clinical signs and symptoms, infectious vs inflammatory host response, diagnosis tests and lab and imaging findings. RT-PCR, reverse transcription-polymerase chain reaction; PCT, procalcitonin; CRP, C-reactive protein; TG, triglycerides; CT, computed tomography; ECHO, echocardiography; EKG, electrocardiogram; EEG, electroencephalography; IL, interleukin; CK, creatine kinase; LDH, lactate dehydrogenase; IgG, immunoglobulin G; BNP, B-type natriuretic peptide; Na, natrium; NK, natural killer; WBC, white blood count; ESR, erythrocyte sedimentation rate; BUN, blood urea nitrogen; C, creatinine; SARS CoV-2, severe acute respiratory syndrome coronavirus 2; MIS-C, multisystem inflammatory syndrome in children and adolescents; US, ultrasound.

References

    1. World Health Organization. Responding to community spread of COVID-19: interim guidance. Available from: https://www.who.int/publications/i/item/responding-to-community-spread-o... [cited 7.3.20].
    1. Du Z., Wang L., Cauchemez S., Xu X., Wang X., Cowling B.J., et al. Risk for transportation of coronavirus disease from Wuhan to other cities in China. Emerg Infect Dis. 2020;26:1049–1052. - PMC - PubMed
    1. Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157–160. - PMC - PubMed
    1. Clerkin K.J., Fried J.A., Raikhelkar J., Sayer G., Griffin J.M., Masoumi A., et al. COVID-19 and cardiovascular disease. Circulation. 2020;2019:1648–1655. - PubMed
    1. Tikellis C., Thomas M.C. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012. 2012 - PMC - PubMed
Cite

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.